(Q37962045)

26 August 2017

title

Modern management of primary B-cell immunodeficiencies (English)

1 reference

26 August 2017

Janine Reichenbach

3

0 references

author name string

Miriam Hoernes

series ordinal

1

1 reference

26 August 2017

Reinhard Seger

series ordinal

2

1 reference

26 August 2017

Janine Reichenbach

series ordinal

3

1 reference

26 August 2017

publication date

1 December 2011

1 reference

Pediatric Allergy & Immunology

26 August 2017

published in

1 reference

26 August 2017

volume

22

1 reference

26 August 2017

issue

8

1 reference

26 August 2017

page(s)

758-769

1 reference

Dissection of B-cell development to unravel defects in patients with a primary antibody deficiency

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Primary B cell immunodeficiencies: comparisons and contrasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Chronic Progressive Poliomyelitis Secondary to Vaccination of an Immunodeficient Child

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Coxsackie B3 virus encephalitis in a patient with agammaglobulinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Protection of mice against vaginal colonisation by Mycoplasma pulmonis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Genotype/phenotype correlations in X-linked agammaglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Clinical and molecular analysis of patients with defects in micro heavy chain gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Update on the hyper immunoglobulin M syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Common variable immunodeficiency: clinical and immunological features of 248 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Common variable immunodeficiency: a new look at an old disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Common variable immunodeficiency: an update on etiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Primary immunodeficiencies: 2009 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Idiopathic late-onset immunoglobulin deficiency. Clinical observations in 50 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

The EUROclass trial: defining subgroups in common variable immunodeficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Common variable immunodeficiency disorders: division into distinct clinical phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Practice parameter for the diagnosis and management of primary immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Incidence and associations of acute renal failure complicating high-dose intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Association of anti-IgA antibodies with adverse reactions to γ-globulin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Self-infusion programmes for immunoglobulin replacement at home: feasibility, safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Immunoglobulin replacement treatment by rapid subcutaneous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Subcutaneous immunoglobulin replacement in primary immunodeficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Subcutaneous immunoglobulin: opportunities and outlook

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Genetic causes of bronchiectasis: primary immune deficiencies and the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Serial lung function tests in primary immune deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Bronchiectasis secondary to primary immunodeficiency in children: longitudinal changes in structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Impact of IgG replacement therapy and antibiotic treatment on the colonization of non-encapsulated Haemophilus influenzae in the nasopharynx in patients with hypogammaglobulinaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Therapeutic strategies in common variable immunodeficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Immunological aspects of new quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Serum bactericidal antibody responses to meningococcal polysaccharide vaccination as a basis for clinical classification of common variable immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Immune competence and switched memory B cells in common variable immunodeficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Pandemic influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Autoimmune manifestations in common variable immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Successful anti-CD20 monoclonal antibody treatment of severe autoimmune hemolytic anemia due to warm reactive IgM autoantibody in a child with common variable immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Primary immunodeficiencies (PIDs) presenting with cytopenias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Inflammatory and autoimmune complications of common variable immune deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Autoimmunity in common variable immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Nonmyeloablative hematopoietic stem cell transplant for X-linked hyper-immunoglobulin m syndrome with cholangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Thymic and bone marrow output in patients with common variable immunodeficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Quantification of κ-deleting recombination excision circles in Guthrie cards for the identification of early B-cell maturation defects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Clinical spectrum of X-linked hyper-IgM syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Effectiveness of Immunoglobulin Replacement Therapy on Clinical Outcome in Patients with Primary Antibody Deficiencies: Results from a Multicenter Prospective Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2011.01236.X

10.1111/J.1399-3038.2011.01236.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference